Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. (Q40457435)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Schmidt-Hieber M

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Blau IW

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Trenschel R

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Andreesen R

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Stuhler G

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Einsele H

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Kanz L

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Keilholz U

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Marinets O

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Beelen DW

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Fauser AA

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Ruutu T

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Uharek L

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Fietz T

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Knauf W

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Hopfenmüller W

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Thiel E

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Freund M

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Casper J

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

19 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

25 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

389-396

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Progress in hematopoietic stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Treosulfan as an effective second-line therapy in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Acute left ventricular failure following melphalan and fludarabine conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Myeloablative and immunosuppressive properties of treosulfan in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705605

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705605

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17310135%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

25 December 2019

1040549449

0 references

1 reference